# AstraZeneca Enhertu showed clinically meaningful and durable responses

- Link: https://www.directorstalkinterviews.com/astrazeneca-enhertu-showed-clinically-meaningful-and-durable-responses/4121108723
- Published: 2023-03-06T08:20:01+00:00
- Author: Ethan Davis

**[AstraZeneca Plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
today provided an results from an analysis of the ongoing DESTINY-PanTumor02 Phase
II trial.

Positive high-level results from an analysis of the ongoing DESTINY-PanTumor02 Phase
II trial showed AstraZeneca and Daiichi Sankyo’s _Enhertu_ (trastuzumab deruxtecan)
met the prespecified target for objective response rate (ORR) and demonstrated durable
response across multiple HER2-expressing advanced solid tumours in heavily pretreated
patients.

_Enhertu_ is a specifically engineered HER2-directed antibody drug conjugate (ADC)
being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.

The DESTINY-PanTumor02 Phase II trial is evaluating the efficacy and safety of _Enhertu_
in patients with locally advanced, unresectable, or metastatic previously treated,
HER2-expressing solid tumours not eligible for curative therapy, including biliary
tract, bladder, cervical, endometrial, ovarian, pancreatic, and rare cancers. The
primary endpoint of the trial is investigator-assessed confirmed ORR and investigator-
assessed duration of response (DoR) is a key secondary endpoint.

The data will be presented at an upcoming medical meeting and shared with global
regulatory authorities.

HER2 is a tyrosine kinase receptor protein expressed on the surface of various tissue
cells throughout the body and is involved in normal cell growth.^(1,2) In some cancer
cells, HER2 expression is amplified or the cells have activating mutations.^(1,3)
While HER2-directed therapies have been used to treat breast, gastric and lung cancers,
more research is needed evaluating their potential role in treating other HER2-expressing
tumour types.^(2,4-6)

> **Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer,
> AstraZeneca, said,** “_Enhertu_ has already demonstrated its potential to improve
> outcomes for patients with HER2-targetable breast, gastric and lung cancers, and
> these positive initial results in other tumour settings with significant unmet
> need are very encouraging. The DESTINY-PanTumor02 results mark an important step
> forward in our understanding of the potential role of _Enhertu_ across multiple
> HER2-expressing tumour types.”

> **Ken Takeshita, Global Head, R&D, Daiichi Sankyo, said,** “The clinically meaningful
> responses seen in the DESTINY-PanTumor02 trial reaffirm our belief in the potential
> of _Enhertu_ across multiple HER2-expressing cancers. The results seen so far 
> across multiple cohorts of the trial will inform next steps of our broad development
> programme as we look to bring this important medicine to as many patients as quickly
> as possible.”

The safety profile observed in patients treated with _Enhertu_ in the DESTINY-PanTumor02
trial was consistent with that seen in other trials of _Enhertu_ with no new safety
signals identified.

Share on: